Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $24.67

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus rating of “Buy” from the eight brokerages that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $24.67.

Several equities research analysts have recently issued reports on STOK shares. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th.

Insider Buying and Selling

In related news, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last quarter. 11.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics during the fourth quarter valued at approximately $63,000. Teacher Retirement System of Texas acquired a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter worth $124,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter.

Stoke Therapeutics Trading Up 1.7 %

STOK opened at $7.69 on Wednesday. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $17.58. The stock has a 50-day moving average of $7.90 and a 200 day moving average of $10.37. The firm has a market cap of $415.86 million, a P/E ratio of -3.66 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, research analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.